Delivering vaccines into the skin without needles and syringes

Expert Review of Vaccines

Volumn 2, Issue 6, 2003, Pages 753-761

  Partidos, Charalambos D ^a  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Adjuvants; Skin immunization; Vaccine delivery; Vaccines

Indexed keywords

BACTERIAL TOXIN; CHOLERA TOXIN; CYTOKINE; DIPHTHERIA TOXOID; DNA VACCINE; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOLOGICAL ADJUVANT; LIPOSOME; OVALBUMIN; TYROSINASE RELATED PROTEIN 2; VACCINE;

ANTIGEN PRESENTING CELL; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ELECTROPORATION; GENE GUN; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; JET INJECTION; MICRONEEDLE ARRAY; NEEDLE; NONHUMAN; PARTICULATE MATTER; PRIORITY JOURNAL; REVIEW; SKIN PENETRATION; SKIN PERMEABILITY; STRATUM CORNEUM; SYRINGE; VACCINATION;

ADMINISTRATION, CUTANEOUS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; NEEDLES; SKIN ABSORPTION; SKIN PHYSIOLOGY; SYRINGES; VACCINATION; VACCINES;

EID: 0348110378     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.6.753     Document Type: Review

References (76)

1. Rappuoli P, Miller HI, Falkow S. The intangible value of vaccination. Science 297, 937-939 (2002).
2. Cohen LL, Blount RL, Cohen RJ et al. Children's expectations and memories of acute distress: short- and long-term efficacy of pain management interventions. J Pediatr. Psychol. 26, 367-374 (2001).
3. Simonsen L, Kane A, Lloyd J et al. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull. World Health Org. 77, 789-800 (1999).
4. Kane A, Lloyd J, Zaffran M et al. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Org. 77, 801-807 (1999).
5. Miller MA, Pisani E. The cost of unsafe injections. Bull. World Health Organ. 77, 808-811 (1999).
6. Debenedictis C, Joubeh S, Zhang G et al. Immune functions of the skin. Clin. Dermatol. 19, 573-585 (2001).
7. Uchi H, Terao H, Koga T, Furue M. Cytokines and chemokines in the epidermis. J. Dermatol. Sci. 24, (Suppl.), S29-S38 (2000).
8. Wang B, Amerio P, Sauder DN. Role of cytokines in epidermal Langerhans migration. J. Leukoc. Biol. 66, 33-39 (1999).
9. Tierney R, Beignon A-S, Rappuoli R et al. Transcutaneous immunisation with tetanus toxoid and mutants of LT as adjuvants elicits strong protective antibody responses. J. Infect. Dis. 188, 753-758 (2003).
10. Matriano JA, Cormier M, Johnson Jet al. Macroflux® microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm. Res. 19, 63-70 (2002).
11. Chen D, Payne LG. Targeting epidermal Langerhans cells by epidermal powder immunization. Cell Res. 12, 97-104 (2002).
12. Seo N, Tokura Y, Nishijima T et al. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc. Natl Acad. Sci. USA 97, 371-376 (2000).
13. Bramson J, Dayball K, Evelegh C et al. Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene Ther. 10, 251-260 (2003).
14. Misra A, Ganga S, Upadhyay P. Needle-free, nonadjuvanted skin immunization by electroporation-enhanced transdermal delivery of diphtheria toxoid and a candidate peptide vaccine against hepatitis B virus. Vaccine 18, 517-523 (2000).
15. Cui Z, Mumper RJ. Chitosan-based nanoparticles for topical genetic immunization. J. Contr. Release 75, 409-419 (2000).
16. Partidos CD, Beignon A-S, Mawas F et al. Immunity under the skin: Potential application for vaccine delivery. Vaccine 21, 776-780 (2003).
17. Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. Nature 391, 851 (1998).
18. Babiuk S, Baca-Estrada ME, Pontarollo R, Foldvari M. Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix). J. Pharm. Pharmacol. 54, 1609-1614 (2002).
19. Paul A, Cevc G, Bachhawat BK Transdermal immunization with large proteins by means of ultradeformable drug carriers. Eur. J. Immunol. 25, 3521-3524 (1995).
20. Bryan JP, Sjogren MH, Macarthy P et al. Persistence of antibody to hepatitis B surface antigen after low-dose, intradermal hepatitis B immunization and response to a booster dose. Vaccine 10, 33-38 (1992).
21. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 356, 152-154 (1992).
22. Dean HJ, Fuller D, Osorio JE. Powder and particle mediated approaches for delivery of DNA and protein vaccines into the epidermis. Comp. Immunol. Microbiol. Infect. Dis. 26, 373-388 (2003).
23. Chen D, Weis KF, Chu Q et al. Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses. J. Virol. 75, 11630-11640 (2001).
24. Chen D, Erickson CA, Endres RL et al. Adjuvantation of epidermal powder immunization. Vaccine 19, 2908-2917 (2001).
25. Chen D, Endres RL, Erickson CA et al. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat. Med. 6, 1187-1190 (2000).
26. Chen D, Periwal SB, Larrivee K et al. Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J. Virol. 75, 7956-7965 (2001).
27. Parent du Chatelet I, Lang J, Schlumbevger M et at. Clinical immunogenicity and tolerance studies of liquid vaccines delivered by jet-injector and a new single-use cartridge (Imule): comparison with standard syringe injection. Vaccine 15, 449-458 (1997).
28. Hoffman PN, Abuknesha RA, Andrews NJ, Samuel D, Lloyd JS. A model to assess the infection potential of jet injectors used in mass immunisation. Vaccine 19, 4020-4027 (2001).
29. McAllister DV, Allen MG, Rausnitz MR Microfabricated microneedles for gene and drug delivery Ann. Rev. Biomed. Engl. 2, 289-313 (2000).
30. Henry S, McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles: a novel approach to transdermal drug delivery. J. Pharm. Sci. 87, 922-925 (1998).
31. Mikszta JA, Alarcon JB, Brittingham JM et al. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med. 8, 415-419 (2002).
32. Bashir SJ, Chew A-L, Anigbogu A. Dreher F, Maibach HI. Physical and physiological effects of stratum corneum tape stripping. Skin Res. Technol. 7, 40-48 (2001).
33. Kahlon R, Hu Y, Orteu CH et al. Optimization of epicutaneous immunization for the induction of CTL. Vaccine 21, 2890-2899 (2003).
34. Tang DC, Shi Z, Curiel DT. Vaccination onto bare skin. Nature 388, 729-730 (1997).
35. Shi Z, Zeng M, Yang G et al. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J. Virol. 75, 11474-11482 (2001).
36. Watabe S, Xin KQ, Ihata A et al. Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 19, 4434-4444 (2001).
37. Nickoloff BJ, Naidu Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J. Am. Acad Dermatol. 30, 535-546 (1994).
38. Nishijima T, Tokura Y, Imokawa G et al. Altered permeability and disordered cutaneous immunoregulatory function in mice with acute barrier disruption. J. Invest. Dermatol. 109, 175-182 (1997).
39. Wood LC, Jackson SM, Elias PM, Grunfeld C, Feingold KR. Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. J. Clin. Invest. 90, 482-487 (1992).
40. Prausnitz MR, Bose VG, Langer R, Weaver JC. Electroporation of mammalian skin:a mechanism to enhance transdermal drug delivery. Proc. Natl Acad. Sci. USA 90, 10504-10508 (1993).
41. Prausnitz MR. A practical assessment of transdermal drug delivery by skin electroporation. Adv. Drug Deliu Rev. 35, 61-76 (1999).
42. Zhang L, Nolan E, Kreitschitz S, Rabussay DP Enhanced delivery of naked DNA to the skin by noninvasive in vivo electroporation. Bioch. Biophys. Acta 1572, 1-9 (2002).
43. Drabick JJ, Glasspool-Malone J, Somiari S, King A, Malone RW. Cutaneous transfection and immune responses to intradermal nucleic: acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol. Ther. 3, 249-255 (2001).
44. Hui S-W. The application of electroporation to transfect hemapoietic: cells and to deliver drugs and vaccines transcutaneously for cancer treatment. Technol. Cancer Res. Treat. 1, 373-384 (2002).
45. Vanbever R, Preat V. In vivo efficacy and safety of skin electroporation. Adv. Drug Del. Rev. 35, 77-88 (1999).
46. Jaafari MR, Foldvari M. Targeting of liposomes to human keratinocytes through adhesive peptides from immunoglobulin domains in the presence of IFN-γ. Drug Deliv. 9, 1-9 (2002).
47. De Jalon EG, Blanco-Prieto MJ, Ygartua R Santoyo S. Topical application of acyclovir-loaded microparticles: quantification of the drug in porcine skin layers. J. Control Release 75, 191-197 (2001).
48. Cui Z, Mumper RJ. The effect of coadministration of adjuvants with a nanoparticle-based genetic vaccine delivery system on the resulting immune responses. Eur. J. Pharm. Biopharm. 55, 11-18 (2003).
49. Cui Z, Baizer L, Mumper RJ. Intradermal immunization with novel plasmid DNA-coated nanopartides via a needle-free injection device. J. Biotech. 102, 105-115 (2003).
50. Mumper RJ, Cui Z. Genetic immunization by jet injection of targeted pDNA-coated nanoparticles. Medthods 31, 255-262 (2003).
51. Baca-Estrada ME, Foldvari M, Babiuk SL, Babiuk LA. Vaccine delivery: lipid-based delivery systems. J. Biotechnol. 83, 91-104 (2000).
52. Cevc G, Gebauer D, Stieber J, Schatzlein A, Blume G. Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim. Biophys. Acta 1368, 201-215 (1998).
53. Spangler B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microb. Rev. 56, 622-647 (1992).
54. Beignon A-S, Briand JP, Muller S, Partidos C.D. Immunisation onto bare skin with heat-labile enteroraxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge. Immunology 102, 344-351 (2001).
55. + T-cells: Immunology 105, 204-212 (2002).
56. Glenn GM. Transcutaneous immunization. In: Vaccine Delivery Strategies. Dietrich G, Goebel W (Ed.), Horizon Scientific Press, Norfolk, UK, 53-81 (2002).
57. Scharton-Kersten T, Yu J, Vassell R et al. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 68, 5306-5313 (2000).
58. Glenn GM, Scharton-Kersten T, Vassell R et al. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161, 3211-3214 (1998).
59. Gockel CM, Bao S, Beagley KW. Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract. Mol. Immunol 37, 537-544 (2000).
60. Godefroy S, Goestch L, Plotnicky-Gilquin H et al. Immunization onto shaved skin with a bacterial enterotoxin aduvant protects mice against Respiratory Syncytial Virus (RSV). Vaccine 21, 1665-1671 (2003).
61. Partidos CD. Antigens onto bare skin: a "painless" paradigm shift in vaccine delivery. Expert Opin. Biol. Ther. 3, 895-902 (2003).
62. Guebre-Xabier M, Hammond SA, Epperson DE et al. Immmunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J. Virol. 77, 5218-5225 (2003).
63. Enioutina EY, Visic D, Daynes RA. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alteration in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine 18, 2753-2767 (200O).
64. Anjuere F, George-Chandy A, Audant F et al. Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses. J. Immunol 170, 1581-1592 (2003).
65. Peppoloni S, Ruggiero P, Contorni M et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines 2, 285-293 (2003).
66. + T-cells and secrete IFN-γ after coapplication onto bare skin. Infect. Immun. 70, 3012-3019 (2002).
67. Glenn GM, Taylor DN, Li X et al. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med 6, 1403-1406 (2000).
68. Guerena-Burgueno F, Hall ER, Taylor DN et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun. 70, 1874-80 (2002).
69. Peachman KK, Rao M, Alving CR. Immunization with DNA through the skin. Methods 31, 232-242 (2003).
70. Levine MM. Can needle-free administration of vaccines become the norm in global immunization? Nat. Med 9, 99-103 (2003).
71. Wester RC, Maibach IH. Animal models for transdermal delivery. In Transdermal of drugs. Kydonieus AF, Berner B, (Eds.), I, CRC Press, FL, USA, 61-70 (1987).
72. Castelain M. Atopic dermititis and delayed hypersensitivity to dust mites. Clin Rev. Allergy Immunol 13, 161-172 (1995).
73. Naleway AL, Belongia EA, Greenlee RT et al. Eczematous skin disease and recall of past diagnoses: implications for smallpox vaccination. Ann Intern. Med 139, 1-7 (2003).
74. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review, part II. Adverse events. Clin Infect. Dis. 37, 251-271 (2003).
75. Arrington J, Braun RP, Dong L et al. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J. Virol 76, 4536-4546 (2002).
76. Drug delivery systems website www.alteatech.com Accessed October 12, 2003